Decline in dispensing pharmacy revenue due to lower drug prices
First written in FY2017-Q2. 14 of 27 entries say "Materialised", first in FY2019-Q1. Latest entry: 2026-08-07.
Bml moved to the "Worse" side of this theme in 2020, 6 years before the typical company in this theme (2026).
The whole theme swung hardest in 2026: 6 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Materialised".
- 2026-08-07MaterialisedResults
「その他事業につきましては、治験実施医療機関支援（SMO）業務で症例獲得数が減少したことに加え、調剤薬局事業で診療報酬改定の影響や高額薬剤処方の減少等により前年同期比7.3％の減収となりました。」
調剤薬局事業で診療報酬改定の影響と高額薬剤処方の減少が減収として顕在化した。 - FY2026-H1MitigatedAnnual report
「In Other businesses, the number of new cases acquired in the pain and urology fields targeted by the clinical trial site management organization (SMO) business increased. In addition, although the dispensing pharmacy business was affected by lower medical service fees (drug prices), revenue increased 5.3% year on year due in part to an increase in prescriptions for high-priced drugs.」
Although the impact of lower drug prices remained, Other businesses increased 5.3% year on year due in part to an increase in prescriptions for high-priced drugs, relatively limiting the revenue impact of lower drug prices. - FY2025MaterialisedAnnual report
「In Other businesses, the clinical trial site management organization (SMO) business completed its work on a large-scale project, while revenue from the dispensing pharmacy business declined due to the impact of lower medical service fees (drug prices). As a result, revenue declined 7.6% compared with the previous fiscal year.」
Other businesses declined 7.6% compared with the previous fiscal year due to the completion of a large-scale SMO project and the impact of lower drug prices. - FY2025-H1MaterialisedAnnual report
「In Other businesses, the clinical trial site management organization (SMO) business completed its work on a large-scale project, while the dispensing pharmacy business was affected by lower medical service fees (drug prices), and the number of prescriptions for COVID-19 treatments and the number of patients at fever outpatient clinics declined. As a result, revenue declined 10.5% year on year.」
Amid the continuing impact of lower drug prices, the decline in prescriptions for COVID-19 treatments and in the number of fever outpatient clinic patients also contributed, resulting in a 10.5% year-on-year decline in Other businesses. - FY2024-Q3MitigatedAnnual report
「In Other businesses, the number of cases acquired increased as the clinical trial site management organization (SMO) business handled a large-scale sleep disorder project. In addition, although the dispensing pharmacy business was affected by lower medical service fees (drug prices), the number of prescriptions increased as fever outpatient clinics expanded amid outbreaks such as influenza, resulting in a 9.2% year-on-year increase in revenue.」
Although the impact of lower drug prices remained, Other businesses increased 9.2% year on year due to an increase in prescriptions resulting from the expansion of fever outpatient clinics. - FY2024-Q2MitigatedAnnual report
「In Other businesses, the number of cases acquired increased as the clinical trial site management organization (SMO) business handled a large-scale sleep disorder project. In addition, although the dispensing pharmacy business was affected by lower medical service fees (drug prices), the number of prescriptions for COVID-19 treatments increased, resulting in a 10.4% year-on-year increase in revenue.」
Although the impact of lower drug prices remained, Other businesses increased 10.4% year on year due to an increase in prescriptions for COVID-19 treatments, relatively limiting the impact of lower drug prices on overall results. - FY2024-Q1RestatedAnnual report
「Although the dispensing pharmacy business was affected by lower medical service fees (drug prices), the number of prescriptions increased as the number of pediatric patients rose amid outbreaks of various infectious diseases. As a result, revenue increased 9.1% year on year.」
Although the impact of lower drug prices continued in the dispensing pharmacy business, the increase in pediatric patients and prescriptions resulting from outbreaks of various infectious diseases more than offset it, and Other businesses increased 9.1% year on year. - FY2023-Q3MaterialisedAnnual report
「Revenue from Other businesses declined 0.2% year on year due to the impact of lower medical service fees (drug prices) in the dispensing pharmacy business.」
The impact of lower medical service fees and drug prices was reflected in a 0.2% year-on-year decline in Other businesses, including the dispensing pharmacy business. - FY2023-Q2MaterialisedAnnual report
「Revenue from Other businesses declined 0.6% year on year due to the impact of lower medical service fees (drug prices) in the dispensing pharmacy business.」
The impact of lower medical service fees and drug prices was reflected in a 0.6% year-on-year decline in Other businesses, including the dispensing pharmacy business. - FY2023-Q1MaterialisedAnnual report
「Revenue from Other businesses declined 2.3% year on year due to the impact of lower medical service fees (drug prices) in the dispensing pharmacy business.」
The impact of lower drug prices due to the revision of medical service fees was reflected in a decline in dispensing pharmacy revenue, and Other businesses declined 2.3% year on year. - FY2022-Q3RestatedAnnual report
「Revenue from Other businesses increased 4.3% year on year despite the impact of lower medical service fees (drug prices) in the dispensing pharmacy business, as revenue benefited from a rebound from the previous year's decline in outpatients associated with the spread of COVID-19.」
Although the impact of lower drug prices continued in the dispensing pharmacy business, Other businesses increased 4.3% year on year due to a rebound from the previous year's decline in outpatients. - FY2022-Q2RestatedAnnual report
「Revenue from Other businesses increased 4.9% year on year despite the impact of lower medical service fees (drug prices) in the dispensing pharmacy business, as revenue benefited from a rebound from the previous year's decline in outpatients associated with the spread of COVID-19.」
Although the impact of lower drug prices due to the revision of medical service fees continues, Other businesses increased 4.9% year on year due to a rebound from the previous year's decline in outpatients. The impact of lower drug prices itself continues to materialize. - FY2022-Q1MaterialisedAnnual report
「Revenue from Other businesses increased 4.4% year on year despite the impact of lower medical service fees (drug prices) in the dispensing pharmacy business, as revenue benefited from a rebound from the previous year's decline in outpatients associated with the spread of COVID-19.」
Although the impact of lower drug prices was stated to be continuing, total revenue from Other businesses increased 4.4% year on year due to a rebound from the previous year's decline in outpatients. - FY2021-Q2MaterialisedAnnual report
「In Other businesses, revenue declined 5.2% year on year because dispensing pharmacy revenue was affected by a decrease in outpatients and lower medical service fees (drug prices), while revenue from the SMO business also declined.」
Dispensing pharmacy revenue was affected by a decrease in outpatients and lower medical service fees and drug prices, while the decline in SMO revenue also contributed, resulting in a 5.2% year-on-year decline in Other businesses. - FY2021-Q1MaterialisedAnnual report
「In Other businesses, revenue declined 7.3% year on year because dispensing pharmacy revenue was affected by a decrease in outpatients and lower medical service fees (drug prices), while revenue from the SMO business also declined.」
Dispensing pharmacy revenue declined due to a decrease in outpatients and lower drug prices, while the decline in SMO revenue also contributed, resulting in a 7.3% year-on-year decline in total revenue from Other businesses. - FY2020MaterialisedAnnual report
「In Other businesses, the dispensing pharmacy business of ㈱岡山医学検査センター remained firm despite the impact of the revision of medical service fees (drug prices), as the opening of new pharmacies, recovery from the impact of the torrential rains in western Japan in the previous fiscal year, and an increase in prescriptions for high-priced hepatitis C drugs contributed to revenue.」
The impact of the drug price revision was again stated as an actual factor, but total revenue from Other businesses increased 3.0% compared with the previous fiscal year due to the contribution from new pharmacies, recovery from the impact of the torrential rains, and an increase in prescriptions for high-priced drugs. - FY2020-Q3MitigatedAnnual report
「In Other businesses, the dispensing pharmacy business of ㈱岡山医学検査センター remained firm as the recovery from the impact of the torrential rains in western Japan in the previous fiscal year and an increase in prescriptions for high-priced hepatitis C drugs contributed to higher revenue. As a result, total revenue from Other businesses increased 3.7% year on year.」
The previous factor behind the decline in revenue due to lower drug prices was not stated, while the dispensing pharmacy business remained firm due to the recovery from the impact of the torrential rains and an increase in prescriptions for high-priced drugs. - FY2020-Q2MitigatedAnnual report
「In Other businesses, the dispensing pharmacy business of ㈱岡山医学検査センター remained firm as the recovery from the impact of the torrential rains in western Japan in the previous fiscal year and an increase in prescriptions for high-priced hepatitis C drugs contributed to higher revenue. As a result, total revenue from Other businesses increased 4.3% year on year.」
The previous factor behind the decline in revenue due to lower drug prices was not cited in the explanation for the quarter. The dispensing pharmacy business remained firm due to the recovery from the impact of the torrential rains in western Japan and an increase in prescriptions for high-priced hepatitis C drugs, while total revenue from Other businesses increased 4.3% year on year. - FY2020-Q1MitigatedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター remained firm during the cumulative first quarter as there was no impact from drug prices (official prices), resulting in a 2.6% year-on-year increase in total revenue from Other businesses.」
There was no impact from drug prices in the first quarter, dispensing pharmacy revenue remained firm, and total revenue from Other businesses also increased 2.6% year on year. - FY2019MaterialisedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in a 10.5% decline in total revenue from Other businesses compared with the previous fiscal year.」
Dispensing pharmacy revenue declined due to the impact of lower drug prices, and total revenue from Other businesses also declined 10.5% compared with the previous fiscal year. - FY2019-Q3MaterialisedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in an 11.1% year-on-year decline in total revenue from Other businesses.」
Dispensing pharmacy revenue declined due to the impact of lower drug prices, and total revenue from Other businesses also declined 11.1% year on year. - FY2019-Q2MaterialisedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in an 11.5% year-on-year decline in total revenue from Other businesses.」
Dispensing pharmacy revenue declined due to the impact of lower drug prices, and total revenue from Other businesses also declined 11.5% year on year. quantified is true, and materialized is true. - FY2019-Q1MaterialisedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in an 8.4% year-on-year decline in total revenue from Other businesses.」
Dispensing pharmacy revenue actually declined due to the impact of lower drug prices, while total revenue from Other businesses also declined 8.4% year on year. - FY2018-Q3RestatedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター increased as the new dispensing pharmacy opened in April of the current fiscal year contributed to revenue, resulting in a 15.8% year-on-year increase in total revenue from Other businesses.」
The new dispensing pharmacy opened in April of the current fiscal year continued to contribute to revenue, and total revenue from Other businesses increased 15.8% year on year. - FY2017RestatedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in a 4.8% decline in total revenue from Other businesses compared with the previous fiscal year.」
The decline in dispensing pharmacy revenue due to lower drug prices and the 4.8% decline in total revenue from Other businesses compared with the previous fiscal year are stated. - FY2017-Q3RestatedAnnual report
「In Other businesses, revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in a 4.5% year-on-year decline in total revenue from Other businesses.」
The decline in dispensing pharmacy revenue due to lower drug prices and the 4.5% year-on-year decline in total revenue from Other businesses are stated again. - FY2017-Q2First statedAnnual report
「Revenue from the dispensing pharmacy business of ㈱岡山医学検査センター declined due to the impact of lower drug prices (official prices), resulting in a 3.6% year-on-year decline in total revenue from Other businesses.」
The lower drug prices (official prices) were reflected in an actual decline in dispensing pharmacy revenue, while total revenue from Other businesses also declined 3.6% year on year.